The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders

Denis Glotz; Jeremy R. Chapman; Vikas R. Dharnidharka; Douglas W. Hanto; Maria C. R. Castro; Hans H. Hirsch; Veronique Leblond; Aneesh K. Mehta; Bruno Moulin; Antonio Pagliuca; Julio Pascual; Alan B. Rickinson; Francesco P. Russo; Ralf U. Trappe; Angela C. Webster; Andreas O. Zuckermann; Thomas G. Gross

doi:10.1097/TP.0b013e318269e64f

The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders

Denis Glotz^*, Jeremy R. Chapman, Vikas R. Dharnidharka, Douglas W. Hanto, Maria C. R. Castro, Hans H. Hirsch, Veronique Leblond, Aneesh K. Mehta, Bruno Moulin, Antonio Pagliuca, Julio Pascual, Alan B. Rickinson, Francesco P. Russo, Ralf U. Trappe, Angela C. Webster, Andreas O. Zuckermann, Thomas G. Gross

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.

Original language	English
Pages (from-to)	784-793
Number of pages	10
Journal	Transplantation
Volume	94
Issue number	8
DOIs	https://doi.org/10.1097/TP.0b013e318269e64f
Publication status	Published - 27 Oct 2012

Keywords

Epstein-Barr virus infection
Immunosuppression
Lymphoproliferative disorder
Transplantation
EPSTEIN-BARR-VIRUS
SOLID-ORGAN TRANSPLANTATION
NON-HODGKIN-LYMPHOMA
PEDIATRIC KIDNEY-TRANSPLANTATION
RENAL-TRANSPLANTATION
LIVER-TRANSPLANTATION
RISK-FACTORS
UNITED-STATES
COLLABORATIVE TRANSPLANT
ANTIVIRAL THERAPY

Access to Document

10.1097/TP.0b013e318269e64f

Cite this

Glotz, D., Chapman, J. R., Dharnidharka, V. R., Hanto, D. W., Castro, M. C. R., Hirsch, H. H., Leblond, V., Mehta, A. K., Moulin, B., Pagliuca, A., Pascual, J., Rickinson, A. B., Russo, F. P., Trappe, R. U., Webster, A. C., Zuckermann, A. O., & Gross, T. G. (2012). The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. Transplantation, 94(8), 784-793. https://doi.org/10.1097/TP.0b013e318269e64f

@article{c2a526a7efbf48a2a1f635101fecaa26,

title = "The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders",

abstract = "Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.",

keywords = "Epstein-Barr virus infection, Immunosuppression, Lymphoproliferative disorder, Transplantation, EPSTEIN-BARR-VIRUS, SOLID-ORGAN TRANSPLANTATION, NON-HODGKIN-LYMPHOMA, PEDIATRIC KIDNEY-TRANSPLANTATION, RENAL-TRANSPLANTATION, LIVER-TRANSPLANTATION, RISK-FACTORS, UNITED-STATES, COLLABORATIVE TRANSPLANT, ANTIVIRAL THERAPY",

author = "Denis Glotz and Chapman, {Jeremy R.} and Dharnidharka, {Vikas R.} and Hanto, {Douglas W.} and Castro, {Maria C. R.} and Hirsch, {Hans H.} and Veronique Leblond and Mehta, {Aneesh K.} and Bruno Moulin and Antonio Pagliuca and Julio Pascual and Rickinson, {Alan B.} and Russo, {Francesco P.} and Trappe, {Ralf U.} and Webster, {Angela C.} and Zuckermann, {Andreas O.} and Gross, {Thomas G.}",

year = "2012",

month = oct,

day = "27",

doi = "10.1097/TP.0b013e318269e64f",

language = "English",

volume = "94",

pages = "784--793",

journal = "Transplantation",

issn = "0041-1337",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "8",

}

Glotz, D, Chapman, JR, Dharnidharka, VR, Hanto, DW, Castro, MCR, Hirsch, HH, Leblond, V, Mehta, AK, Moulin, B, Pagliuca, A, Pascual, J, Rickinson, AB, Russo, FP, Trappe, RU, Webster, AC, Zuckermann, AO & Gross, TG 2012, 'The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders', Transplantation, vol. 94, no. 8, pp. 784-793. https://doi.org/10.1097/TP.0b013e318269e64f

TY - JOUR

T1 - The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders

AU - Glotz, Denis

AU - Chapman, Jeremy R.

AU - Dharnidharka, Vikas R.

AU - Hanto, Douglas W.

AU - Castro, Maria C. R.

AU - Hirsch, Hans H.

AU - Leblond, Veronique

AU - Mehta, Aneesh K.

AU - Moulin, Bruno

AU - Pagliuca, Antonio

AU - Pascual, Julio

AU - Rickinson, Alan B.

AU - Russo, Francesco P.

AU - Trappe, Ralf U.

AU - Webster, Angela C.

AU - Zuckermann, Andreas O.

AU - Gross, Thomas G.

PY - 2012/10/27

Y1 - 2012/10/27

N2 - Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.

AB - Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.

KW - Epstein-Barr virus infection

KW - Immunosuppression

KW - Lymphoproliferative disorder

KW - Transplantation

KW - EPSTEIN-BARR-VIRUS

KW - SOLID-ORGAN TRANSPLANTATION

KW - NON-HODGKIN-LYMPHOMA

KW - PEDIATRIC KIDNEY-TRANSPLANTATION

KW - RENAL-TRANSPLANTATION

KW - LIVER-TRANSPLANTATION

KW - RISK-FACTORS

KW - UNITED-STATES

KW - COLLABORATIVE TRANSPLANT

KW - ANTIVIRAL THERAPY

U2 - 10.1097/TP.0b013e318269e64f

DO - 10.1097/TP.0b013e318269e64f

M3 - Article

SN - 0041-1337

VL - 94

SP - 784

EP - 793

JO - Transplantation

JF - Transplantation

IS - 8

ER -

The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders

Abstract

Keywords

Access to Document

Fingerprint

Cite this